maribavir · Takeda Pharms Usa · NDA 215596
Livtencity
Earliest generic entry, as listed
11 Oct 2043
Blocked by patent: US 12295940, US 12527771.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12295940 | substance, product | 11 Oct 2043 |
| US 12527771 | substance, product | 11 Oct 2043 |
| US 12213989 | use U-4137 | 18 Nov 2042 |
| US 12433907 | use U-4289 | 18 Nov 2042 |
| US 12447170 | use U-4328 | 18 Nov 2042 |
| US 11684632 | use U-3650 | 4 Jan 2032 |
| US 12447169 | use U-4329 | 27 Oct 2031 |
| US 12661368 | use U-4572 | 27 Oct 2031 |
Exclusivities · 2 unexpired
| ODE-388 | orphan drug (7 years) | 23 Nov 2028 |
| NCE | new chemical entity (5 years) | 23 Nov 2026 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Exclusivity expires within 90 days NCE · 215596-00123 Nov 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215596 · 001 · RLD | tablet, oral | 200MG | 11 Oct 2043 |